The Alzheimer's Biomarker Consortium–Down Syndrome (ABC-DS)

Authors

• Benjamin L. Handen, University of PittsburghFollow
• Mark Mapstone, University of California Irvine
• Sigan Hartley, University of Wisconsin-Madison
• Howard Andrews, Columbia University Medical Center
• Brad Christian, University of Wisconsin-Madison
• Joseph H. Lee, Columbia University
• Dana Tudorascu, University of Pittsburgh
• Christy Hom, University School of Medicine
• Beau M. Ances, Washington University School of Medicine in St. Louis
• Shahid Zaman, University of Cambridge
• Sharon Krinsky-McHale, New York State Office for People with Developmental Disabilities
• Adam M. Brickman, Columbia University
• H. Diana Rosas, Harvard University
• Annie Cohen, University of Pittsburgh
• Melissa Petersen, Texas College of Osteopathic Medicine
• Sid O'Bryant, Texas College of Osteopathic Medicine
• Jordan P. Harp, University of KentuckyFollow
• Frederick Schmitt, University of KentuckyFollow
• Lauren Ptomey, University of Kansas
• Jeffrey Burns, University of Kansas
• Ira T. Lott, University of California Irvine
• Florence Lai, Harvard University
• Wayne Silverman, University of California Irvine
• Charles Laymon, University of Pittsburgh
• Elizabeth Head, University of California Irvine

Abstract

INTRODUCTION: Virtually all adults with Down syndrome (DS) will accumulate the neuropathologies associated with Alzheimer's disease (AD) by age 40, with the majority having a clinical dementia diagnosis by their middle 50s. METHODS: This paper complements a 2020 publication describing the Alzheimer's Biomarker Consortium–Down Syndrome (ABC-DS) methodology by highlighting protocol changes since initial funding in 2015. It describes available clinical, neuropsychological, neuroimaging, and biofluid data and bio-specimen repository. Ten years of accomplishments are summarized. RESULTS: Over 500 adults with DS and 59 sibling controls have been enrolled since 2015 with nearly 800 follow-up visits. More than 900 magnetic resonance imaging (MRI), 800 amyloid positron emission tomography (PET), and 600 tau PET scans have been conducted; multiple omics data have been generated using over 1100 blood and 100 cerebrospinal fluid (CSF) samples. DISCUSSION: ABC-DS is the largest U.S.-based, multi-site (including the United Kingdom and Puerto Rico), longitudinal biomarker initiative to target adults with DS at risk for AD. Highlights: The Alzheimer's Biomarker Consortium—Down Syndrome (ABC-DS) is entering its 10th year. Over 500 adults with Down syndrome (DS) and 59 sibling controls have been enrolled. More than 900 magnetic resonance imaging (MRI), 800 amyloid positron emission tomography (PET), and 600 tau PET scans have been conducted. Multiple omics data have been generated using over 1100 blood and 100 cerebrospinal fluid (CSF) samples. It is positioned to continue to make substantial contributions to the DS field.

Document Type

Article

Publication Date

5-1-2025

Notes/Citation Information

Publisher Copyright: © 2025 The Author(s). Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.

Digital Object Identifier (DOI)

10.1002/alz.70294

Archival?

Archival

Repository Citation

Handen, Benjamin L.; Mapstone, Mark; Hartley, Sigan; Andrews, Howard; Christian, Brad; Lee, Joseph H.; Tudorascu, Dana; Hom, Christy; Ances, Beau M.; Zaman, Shahid; Krinsky-McHale, Sharon; Brickman, Adam M.; Rosas, H. Diana; Cohen, Annie; Petersen, Melissa; O'Bryant, Sid; Harp, Jordan P.; Schmitt, Frederick; Ptomey, Lauren; Burns, Jeffrey; Lott, Ira T.; Lai, Florence; Silverman, Wayne; Laymon, Charles; and Head, Elizabeth, "The Alzheimer's Biomarker Consortium–Down Syndrome (ABC-DS)" (2025). Psychology Faculty Publications. 305.
https://uknowledge.uky.edu/psychology_facpub/305